Last updated: October 22, 2026
Ferric oxyhydroxide, marketed primarily as sucroferric oxyhydroxide under the brand Velphoro, is an oral phosphate binder for adults with chronic kidney disease on dialysis. Its commercial position is supported by low pill burden, calcium-free chemistry, and established use in hemodialysis and peritoneal dialysis. The principal risks are payer pressure, competition from sevelamer and ferric citrate, limited market expansion in dialysis, and eventual generic entry.
Velphoro remains a specialty nephrology product rather than a high-growth pharmaceutical platform. Its financial trajectory depends on share gains within the dialysis phosphate-binder market, international reimbursement, and the timing of generic or authorized-generic competition.
What is ferric oxyhydroxide and which drug contains it?
Ferric oxyhydroxide is the iron-based phosphate-binding component of sucroferric oxyhydroxide. Velphoro is a chewable tablet containing a mixture of polynuclear iron(III)-oxyhydroxide, sucrose, and starches. It is manufactured and commercialized by CSL Vifor, following CSL’s acquisition of Vifor Pharma in 2022.
The FDA approved Velphoro in November 2013 for the control of serum phosphorus levels in adults with chronic kidney disease receiving dialysis.[1] The drug is not an intravenous iron replacement product. Its primary pharmacology is gastrointestinal phosphate binding, with minimal systemic iron absorption relative to therapeutic iron products.
Key product characteristics
| Attribute |
Velphoro |
| Active substance |
Sucroferric oxyhydroxide |
| Drug class |
Non-calcium, iron-based phosphate binder |
| Dosage form |
Chewable tablet |
| Initial U.S. approval |
November 2013 |
| FDA indication |
Hyperphosphatemia in adults with CKD receiving dialysis |
| Initial dose |
1,000 mg iron equivalent daily, divided with meals |
| Main competitors |
Sevelamer, calcium acetate, ferric citrate, lanthanum carbonate |
| Commercial owner |
CSL Vifor |
| Primary market |
Dialysis and renal specialty care |
Velphoro’s commercial value comes from its ability to control phosphate with fewer tablets than several older binders. The tradeoff is gastrointestinal tolerability, dark stool discoloration, administration with meals, and the need to monitor iron parameters in selected patients.
How large is the ferric oxyhydroxide market?
The addressable market is the global oral phosphate-binder market, not the entire chronic kidney disease drug market. Demand is driven by the number of dialysis patients, phosphate-control guidelines, treatment persistence, formulary access, and average daily tablet burden.
The global dialysis population is measured in the millions, with the United States accounting for more than 500,000 people receiving maintenance dialysis in recent U.S. estimates.[2] Most dialysis patients require phosphate-lowering therapy, but product selection varies by country and payer.
Market structure
| Segment |
Commercial role |
| Sevelamer carbonate/hydrochloride |
Broadly used, established, increasingly exposed to generic pricing |
| Calcium acetate |
Low-cost option; limited by calcium loading and vascular-calcification concerns |
| Sucroferric oxyhydroxide |
Premium, low-pill-burden, calcium-free option |
| Ferric citrate |
Competes on phosphate control and iron delivery |
| Lanthanum carbonate |
Smaller branded and generic segment |
| Aluminum-based binders |
Restricted or short-term use because of toxicity concerns |
Velphoro’s strongest market argument is pill burden. The prescribing information reports lower tablet requirements than sevelamer carbonate in a comparative clinical study.[1] That advantage matters because phosphate binders must be taken with meals and adherence is difficult when patients take multiple medicines.
The market is mature in the United States and Western Europe. Growth is more likely to come from conversion among existing dialysis patients than from a large increase in treated prevalence. Emerging-market growth is constrained by dialysis access, reimbursement, and the affordability of branded phosphate binders.
What are the financial drivers for Velphoro?
Velphoro generates specialty-pharma revenue through chronic, recurring use. Its financial profile has four main drivers:
- Patient volume in dialysis.
- Net price after rebates and tenders.
- Conversion from sevelamer and calcium-based binders.
- Generic erosion after patent and regulatory barriers fall.
Vifor Pharma reported Velphoro as one of its key commercial products before the CSL acquisition. Company disclosures described continued growth in Velphoro sales as the product expanded across markets and gained use based on pill-burden and phosphate-control advantages.[3] CSL now reports the product within its Vifor business rather than as a separately listed public-company segment, which reduces transparency into standalone revenue and operating margin.
Financial trajectory
| Period |
Commercial interpretation |
| 2013-2016 |
U.S. launch and clinical adoption phase |
| 2017-2020 |
International expansion and conversion from older binders |
| 2021-2022 |
Mature branded growth before and around the Vifor-CSL transaction |
| 2023-2025 |
Portfolio integration under CSL, with growth dependent on share and pricing |
| Post-generic entry |
Likely rapid net-price compression and volume migration |
Velphoro has attractive specialty-product economics because manufacturing is more differentiated than a conventional small-molecule tablet. The product is a complex iron-sucrose matrix rather than a simple active pharmaceutical ingredient. That complexity may delay generic substitution, but it does not eliminate the risk.
The principal financial limitation is market size. The product treats a defined dialysis population, and most patients are already exposed to a phosphate binder. A higher share of a finite patient pool, rather than broad disease expansion, is the central commercial opportunity.
What patents protect Velphoro and sucroferric oxyhydroxide?
Velphoro’s protection has historically relied on composition, pharmaceutical formulation, manufacturing, and use claims covering iron oxyhydroxide materials and their administration as phosphate binders.
The relevant U.S. patent landscape includes patents assigned to Vifor or related entities and listed in FDA’s Orange Book for Velphoro. Orange Book listings can change through patent expiry, delisting, corrections, or regulatory updates. The operative commercial barrier is therefore the current FDA listing combined with ANDA litigation and any settlement restrictions.[4]
Patent categories
| Patent category |
Protection target |
Generic relevance |
| Composition |
Sucroferric or iron oxyhydroxide material |
Establishes the product’s core identity |
| Formulation |
Chewable tablet, excipients, stability, and dosage form |
May require design-around work |
| Manufacturing |
Preparation of the iron-sucrose matrix and particle properties |
Can create process-development barriers |
| Method of use |
Treatment of hyperphosphatemia in dialysis patients |
Relevant to label strategy and skinny-label risk |
| Product-by-process or characterization |
Physical and chemical attributes |
May complicate equivalence demonstrations |
Public patent databases identify a family of Vifor-related patents covering iron oxyhydroxide compositions and pharmaceutical applications, including U.S. Patent No. 8,609,675 and related continuation or counterpart filings. Patent expiration must be assessed by family, terminal disclaimers, patent-term adjustment, and listed Orange Book status rather than by the earliest publication alone.[4,5]
A patent estate can be commercially strong even when the core composition patent is approaching expiry if formulation, manufacturing, or regulatory exclusivity barriers remain active. The opposite is also true: multiple listed patents may provide limited practical protection if an ANDA applicant can invalidate or design around them.
When does ferric oxyhydroxide lose exclusivity?
Velphoro’s U.S. regulatory exclusivity has expired. The commercial question is patent and ANDA timing.
The 2013 approval was not supported by new chemical entity exclusivity because sucroferric oxyhydroxide was approved as a complex iron-based product rather than as a conventional new molecular entity. The product’s continuing protection is therefore primarily patent-based, supported by prescription demand and manufacturing complexity.
Exclusivity timeline
| Event |
Date or status |
| FDA approval of Velphoro |
November 2013 |
| New chemical entity exclusivity |
Not the primary protection mechanism |
| U.S. regulatory exclusivity |
Expired |
| Orange Book patent protection |
Dependent on listed patents and patent-term calculations |
| ANDA Paragraph IV risk |
Present once applicants challenge listed patents |
| Generic launch |
Dependent on litigation outcome, settlement terms, and final approval |
There is no single global expiry date for ferric oxyhydroxide. Patent rights differ by jurisdiction, and product launch timing can be restricted by litigation settlements even after a patent challenge.
Which companies are challenging Velphoro patents?
Generic manufacturers can challenge Velphoro through an ANDA containing a Paragraph IV certification. That certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic.
Publicly available FDA and federal court records should be used to identify each active ANDA applicant and litigation docket. The commercial significance of a challenge depends on whether the applicant has filed a complete ANDA, whether the patent holder filed suit within the statutory period, and whether a 30-month stay applies.
A Paragraph IV filing does not guarantee launch. The applicant still needs FDA approval, satisfactory bioequivalence or pharmaceutical-equivalence evidence, and resolution of any injunction or settlement restriction.
Generic entry scenarios
| Scenario |
Market impact |
| No approved ANDA before patent expiry |
Continued branded sales, with rising payer pressure |
| Single generic launch |
Rapid price reduction, but possible limited substitution |
| Multiple generic launches |
Accelerated net-price erosion and loss of formulary leverage |
| Authorized generic |
Faster price competition while retaining some manufacturer control |
| Patent settlement with delayed entry |
Managed erosion beginning on a negotiated date |
| Manufacturing or equivalence delay |
Extended branded revenue despite nominal patent expiry |
Because Velphoro is a complex iron-based chewable product, generic development may require more than routine tablet formulation. The applicant must address active-moiety characterization, release behavior, iron content, phosphate-binding performance, and product sameness. These requirements can delay entry but do not create biologic-like protection.
What is the FDA and Orange Book status of Velphoro?
Velphoro is FDA-approved and listed as a prescription drug for hyperphosphatemia in adults with CKD receiving dialysis.[1] It is not a biologic, so biosimilar regulation does not apply. Generic competition would proceed through the ANDA pathway rather than the abbreviated biosimilar pathway.
The Orange Book remains the central U.S. source for listed patents, exclusivity information, dosage-form data, and therapeutic-equivalence codes.[4] A current Orange Book review is necessary for transaction diligence because listed patents and expiry details can change.
The key regulatory issue is that Velphoro is a complex oral product. A generic applicant may face a higher development burden than an applicant copying a conventional immediate-release small molecule. The FDA’s treatment of complex drug products can affect the scope of required evidence and the timing of approval.[6]
How does Velphoro compare with ferric citrate and sevelamer?
Velphoro versus sevelamer
Velphoro’s principal advantage is lower pill burden. Sevelamer has broad clinical familiarity, extensive generic availability, and strong formulary penetration. Its principal commercial weakness is the number of tablets required at standard doses.
Velphoro is more exposed to branded pricing pressure, while sevelamer is more exposed to generic substitution. A payer may prefer sevelamer on cost and Velphoro on adherence, pill burden, or selected patient characteristics.
Velphoro versus ferric citrate
Ferric citrate provides phosphate binding with iron delivery and is marketed in the United States as Auryxia by Keryx Biopharmaceuticals, now part of Akebia Therapeutics. The products compete for patients in whom iron management and phosphate control are both relevant.
Velphoro has a distinct chewable formulation and a different iron-phosphate binding matrix. Ferric citrate has its own patent and regulatory history, so the two products face separate generic and litigation timelines.
Velphoro versus calcium acetate
Calcium acetate is inexpensive and widely available. Its use can be limited by calcium loading, especially in patients with vascular calcification risk or abnormal calcium-phosphate balance. Velphoro’s calcium-free profile supports premium positioning but does not guarantee reimbursement.
What manufacturing and intellectual-property barriers protect the product?
The principal manufacturing barrier is the production of a reproducible polynuclear iron oxyhydroxide-sucrose matrix with consistent phosphate-binding behavior. Relevant technical variables include particle size, iron oxidation state, sucrose association, moisture, chewability, dissolution or dispersion behavior, and stability.
These characteristics can affect both product performance and regulatory comparability. A generic applicant may be able to avoid a process patent while still facing analytical and clinical development costs.
The barrier is lower than for a biologic because Velphoro is an oral non-biologic product. It is higher than for a simple salt tablet because the active material is a complex coordination matrix with functional binding properties.
What licensing deals and corporate transactions affect ferric oxyhydroxide?
The major corporate event is CSL’s acquisition of Vifor Pharma, completed in 2022. The transaction transferred control of Vifor’s renal and iron portfolio, including Velphoro, to CSL.[7]
Before the acquisition, Vifor used regional commercial partnerships and licensing arrangements across its specialty portfolio. Velphoro’s economics therefore vary by territory depending on direct commercialization, distribution, licensing, and tender arrangements. CSL’s ownership gives the product access to a larger global healthcare platform but also places it within a broader portfolio that includes intravenous iron and nephrology products.
No biosimilar licensing structure applies to Velphoro. Any future transaction would be more likely to involve regional commercialization, a generic or authorized-generic strategy, or a portfolio sale than biosimilar partnering.
What revenue exposure does Velphoro create for CSL?
Velphoro is strategically important but not transformational for CSL. It produces recurring revenue from a chronic dialysis indication and complements CSL Vifor’s renal portfolio. Its revenue exposure is concentrated in a specialty market with relatively predictable patient demand.
The principal downside risks are:
- Generic entry and net-price erosion.
- U.S. formulary restrictions.
- Dialysis-provider purchasing pressure.
- Substitution by low-cost sevelamer or calcium acetate.
- Slower-than-expected conversion from established binders.
- Loss of exclusivity in major markets.
- Manufacturing failures or supply interruptions.
The principal upside drivers are:
- Increased use in patients with high pill burden.
- Share gains against calcium-based binders.
- Broader international reimbursement.
- Continued dialysis population growth.
- Premium positioning based on adherence and convenience.
- Delayed generic entry caused by patent litigation or complex-product development.
Key Takeaways
- Ferric oxyhydroxide is commercially represented by Velphoro, a calcium-free oral phosphate binder for adults on dialysis.
- Velphoro’s main competitive advantage is lower pill burden compared with several sevelamer regimens.
- The market is mature, with growth driven mainly by conversion and share gains rather than new disease penetration.
- CSL owns the product following its acquisition of Vifor Pharma in 2022.
- U.S. regulatory exclusivity has expired; patent listings, ANDA challenges, litigation, and settlement terms determine practical generic timing.
- Velphoro is a non-biologic complex oral product, so biosimilar risk does not apply.
- Generic development is more technically demanding than copying a conventional small-molecule tablet but remains commercially feasible.
- Revenue should remain recurring until generic entry, after which price erosion could be rapid if multiple ANDA products launch.
- The strongest ongoing defenses are product differentiation, manufacturing know-how, formulation complexity, and nephrology-market relationships.
FAQs
Is ferric oxyhydroxide the same as sucroferric oxyhydroxide?
No. Sucroferric oxyhydroxide is the pharmaceutical product name used for Velphoro’s iron-based phosphate-binding matrix. Ferric oxyhydroxide is a broader chemical description.
Does ferric oxyhydroxide treat iron-deficiency anemia?
Velphoro is indicated as a phosphate binder, not as an iron-replacement therapy. Its formulation should not be treated as interchangeable with intravenous iron or oral iron products approved for anemia.
Is Velphoro a biologic or biosimilar product?
No. Velphoro is a non-biologic prescription drug. Generic competition would use the ANDA pathway, not the biosimilar pathway.
What is the biggest commercial threat to Velphoro?
The largest threat is generic entry combined with payer substitution toward low-cost sevelamer or calcium acetate. A competing iron-based binder, such as ferric citrate, is a secondary product-level threat.
Why can Velphoro maintain value after regulatory exclusivity expires?
Chronic prescribing, physician familiarity, pill-burden advantages, manufacturing complexity, and payer contracts can preserve revenue after regulatory exclusivity ends. Those defenses weaken substantially once multiple therapeutically equivalent generics become available.
References
- U.S. Food and Drug Administration. (2023). Velphoro (sucroferric oxyhydroxide) prescribing information.
- United States Renal Data System. (2023). 2023 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases.
- Vifor Pharma Ltd. (2021). Annual report 2021.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- United States Patent and Trademark Office. (2024). Patent Center and Patent Public Search.
- U.S. Food and Drug Administration. (2023). Guidance for industry: ANDAs for certain highly purified synthetic peptides and complex drug products.
- CSL Limited. (2022). Completion of acquisition of Vifor Pharma.
